Improvement of Disease Management and Cost Effectiveness in Chinese Patients with Ankylosing Spondylitis Using a Smart-Phone Management System: A Prospective Cohort Study
Table 3
Characteristics of disease activity at baseline and a mean (SD) follow-up of 13.3 (5.9) months.
Characteristics
ID/LDA at baseline (n=445, 57.2%)
Active at baseline (n=332, 42.7%)
Maintainer of ID/LDA (n=410, 92.1%)
Patients with relapse (n=35, 7.9%)
P value
Maintainer of active disease (n=127, 38.2%)
New achiever of ID/LDA (n=205, 61.7%)
P value
Age, mean (S.D.), years
30.2 (9.1)
29.8 (7.6)
0.785
30.8 (8.6)
30.6 (8.3)
0.816
Disease duration, mean (S.D.), years
7.6 (6.2)
7.3 (5.6)
0.787
9.0(6.1)
9.3(6.1)
0.714
Number of self-assessments, mean (S.D.)
5.0 (2.7)
3.3 (1.8)
<0.001
4.5(2.5)
5.6(3.1)
<0.001
Male sex, %
79.8
88.6
0.207
89.8
83.9
0.133
ASDAS at baseline, mean (S.D.)
1.4 (0.5)
1.5 (0.4)
0.031
3.2 (0.8)
3.0 (0.8)
0.134
Smoker, %
24.7
40.0
0.047
44.0
32.8
0.042
NSAIDs at baseline, %
98.1
99.8
0.448
97.9
99.4
0.263
TNFi at baseline, %
19.2
13.8
0.479
24.5
29.8
0.359
csDMARDs at baseline, %
64.0
72.4
0.363
66.0
68.5
0.679
TNFi during the follow-up perio, %
29.9
27.3
0.755
32.3
45.6
0.016
TNFi during the follow-up period: used TNFi at any point beginning from the time of enrolment in the registry (the first visit) and during the follow-up visits. ID: inactive disease, LDA: low disease activity, ASDAS: Ankylosing Spondylitis Disease Activity Score; NSAIDs: non-steroidal anti-inflammatory drugs; TNFi: TNF inhibitors; csDMARDs: conventional synthetic disease modifying anti-rheumatic drug; P < 0.05.
